Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2015-001718-80-NL
EUCTR2015-001718-80-NLActive, not recruitingPhase 1

A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF) - PRM-151G-101

Promedior, Inc0 sites98 target enrollmentStarted: July 29, 2015Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
98
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1. Subjects must be =18 years of age at the time of signing the Informed Consent Form (ICF);
  • •2. Subjects must voluntarily sign an ICF;
  • •3. Subjects must have a pathologically confirmed diagnosis of PMF as per the WHO diagnostic criteria or post ET/PV MF;
  • •4. At least Grade 2 marrow fibrosis according to the WHO Grading of Bone Marrow Fibrosis;
  • •5. Intermediate-1, intermediate -2, or high risk disease according to the IWG-MRT Dynamic International Prognostic Scoring System;
  • •6. A bone marrow biopsy must be performed within four weeks prior to Cycle 1 Day 1 treatment to establish the baseline fibrosis score;
  • •7. Subjects must not be candidates for ruxolitinib based on EITHER: a. Platelet count < 50 x 10^9/L, OR b. Hgb < 100 g/L, have received = 2 units PRBC in the 12 weeks prior to study entry, and be intolerant of or had inadequate response to ruxolitinib;
  • •8. Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.
  • •9. Life expectancy of at least twelve months;
  • •10. At least four weeks must have elapsed between the last dose of any MF-directed drug treatments for myelofibrosis (including investigational therapies) and study enrollment;
  • •11. Recovery to = Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia;
  • •12. Women of child bearing potential (WCBP), defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if < 55 years or 12 months if > 55 years, must have a negative serum pregnancy test within four weeks prior to the first dose of study drug and must agree to use highly effective methods of birth control throughout the study. Highly effective methods of contraception include combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation by oral, intravaginal, or transdermal administration; progestogen-only hormonal contraception associated with inhibition of ovulation by oral, injectable, or implantable administration; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; partner vasectomy, and total abstinence (only if total abstinence is the preferred method and usual lifestyle of the subject). Adequate contraceptive use should be continued until 28 days after the final dose of the study drug.
  • •13. Ability to adhere to the study visit schedule and all protocol requirements;
  • •14. Must have an adequate organ function as demonstrated by the following:
  • •o ALT (SGPT) and/or AST (SGOT) < 3 x upper limit of normal (ULN), or < 4 x ULN (if upon judgment of the treating physician, it is believed to be due to extramedullary hematopoiesis [EMH] related to MF);
  • •o Direct bilirubin < 1.5 x ULN; or < 2 x ULN (if upon judgment of the treating physician, it is believed to be due to EMH related to MF);
  • •o Serum creatinine < 2.5x ULN.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 49
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 49

Exclusion Criteria

  • •1. White blood cell count > 25 x 10^9/L or > 10% peripheral blood blasts;
  • •2. Other invasive malignancies within the last 3 years, except non-melanoma skin cancer and localized cured prostate and cervical cancer;
  • •3. History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months;
  • •4. Presence of active serious infection;
  • •5. Any serious, unstable medical or psychiatric condition that would prevent, (as judged by the Investigator) the subject from signing the informed consent form or any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study;
  • •6. Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection;
  • •7. Organ transplant recipients other than bone marrow transplant;
  • •8. Women who are pregnant or lactating.

Investigators

Similar Trials

Completed
Phase 2
A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)myelofibrosebone marrow replaced by scarMyelofibrosis
NL-OMON44095Promedior, Inc10
Active, not recruiting
Phase 1
A study to test intravenous PRM-151 to see how different doses of PRM-151 act in the body and blood of people with myelofibrosis - a disorder of the bone marrow, in which the marrow is replaced by scar (fibrous) tissue.
EUCTR2015-001718-80-FRPromedior, Inc84
Active, not recruiting
Phase 1
A study to test intravenous PRM-151 to see how different doses of PRM-151 act in the body and blood of people with myelofibrosis - a disorder of the bone marrow, in which the marrow is replaced by scar (fibrous) tissue.Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)MedDRA version: 21.0 Level: LLT Classification code 10074689 Term: Post polycythemia vera myelofibrosis System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0 Level: LLT Classification code 10074690 Term: Post essential thrombocythemia myelofibrosis System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10028537 Term: Myelofibrosis System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-001718-80-DEPromedior, Inc84
Active, not recruiting
Phase 1
A study to test intravenous PRM-151 to see how different doses of PRM-151 act in the body and blood of people with myelofibrosis - a disorder of the bone marrow, in which the marrow is replaced by fibrotic tissue.Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-001718-80-ITPROMEDIOR, INC.124
Completed
Phase 2
A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)IPFlung fibrosis10024967
NL-OMON43714Promedior, Inc21